Ledger.Open graph →
SEC Form D · Amendment · filed January 18, 2017

Lysosomal Therapeutics, Inc

Offering
$26.1M
Sold
$26.1M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (19)

Steven E. Hall · Cambridge, MADirectorClay E. Thorp · Cambridge, MADirectorCornelis Been · Cambridge, MAExec · DirectorDaniel Geffken · Cambridge, MAExecBernard Davitian · Cambridge, MADirectorCarole Neuchterlein · Cambridge, MADirectorBruce L. Booth · Cambridge, MADirectorRobert Carpenter · Cambridge, MAExec · DirectorBruce L. Booth · Cambridge, MADirectorAnabatic GP, LLC · Oak Brook, ILExecLukasz Gottwald · El Segundo, CAExec · Director22Nw Fund GP, LLC · Seattle, WAExec · DirectorAnabatic Investment Partners, LLC · Oak Brook, ILDirector22Nw, LP · Seattle, WAExec · DirectorRussell J. Matthews · Denver, CODirectorWarren J. Olsen · Denver, CODirectorDavid Bree · GEORGETOWN, GRAND CAYMAN, Cayman IslandsExec · DirectorKevin E. Harrington · Boca Raton, FLDirectorThomas E. Lynch · Boca Raton, FLDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗